The manufacture and selling of counterfeit medicines is an issue of increasing concern throughout the world. There are potentially fatal consequences for those who inadvertently take such products.

The ABPI and its member companies work very closely with the Medicines and Healthcare products Regulatory Agency (MHRA) to develop effective measures to prevent the entry of counterfeit medicines into the UK. We have been very active in the development of a new European Directive which it is hoped will be adopted in the near future and which will provide stricter controls on manufacture, supply and trading of medicinal products which will provide greater protection against this dangerous trade.

Last modified: 20 September 2023

Last reviewed: 20 September 2023